Target Name: ZNF384
NCBI ID: G171017
Review Report on ZNF384 Target / Biomarker Content of Review Report on ZNF384 Target / Biomarker
ZNF384
Other Name(s): FLJ59043 | Trinucleotide repeat containing 1 | Zinc finger protein 384, transcript variant 2 | NP | Zinc finger protein 384 (isoform a) | CAS-interacting zinc finger protein | CAG repeat protein 1 | Nuclear matrix transcription factor 4 | ERDA2 | ZNF384 variant 2 | Expanded repeat domain, CAG/CTG 2 | Nuclear matrix protein 4 | trinucleotide repeat-containing gene 1 protein | zinc finger protein 384 | expanded repeat domain, CAG/CTG 2 | Zinc finger protein 384 | Zinc finger protein 384, transcript variant 7 | CAGH1 | Trinucleotide repeat-containing gene 1 protein | CAGH1A | nuclear matrix transcription factor 4 | ZN384_HUMAN | TNRC1 | ZNF384 variant 7 | Cas-interacting zinc finger protein | CIZ | Zinc finger protein 384 (isoform d) | NMP4

ZNF384: A Potential Drug Target and Biomarker

Zinc finger nucleosome 384 (ZNF384) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. ZNF384 is a key component of the nuclear organizing structure, which is responsible for the proper functioning of chromatin. It plays a critical role in the regulation of gene expression and has been linked to various diseases, including cancer.

The Importance of ZNF384 as a Drug Target

ZNF384 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the key reasons for its potential as a drug target is its unique structure, which allows it to interact with various signaling pathways. ZNF384 is a small RNA molecule that contains a conserved domain that is similar to other zinc finger proteins. This conserved domain is important for its ability to interact with various signaling pathways, including the PI3K/Akt signaling pathway.

Additionally, ZNF384 has been shown to play a critical role in the regulation of cell growth and has been linked to the development of various types of cancer. For example, studies have shown that high levels of ZNF384 are associated with the development of breast cancer. This suggests that targeting ZNF384 may be an effective way to treat breast cancer.

The Potential of ZNF384 as a Biomarker

In addition to its potential as a drug target, ZNF384 has also been identified as a potential biomarker for various types of cancer. The ability of ZNF384 to be expressed and processed from RNA to protein suggests that it could be used as a biomarker for cancer.

Studies have shown that ZNF384 is expressed in various types of cancer, including breast cancer, lung cancer, and colorectal cancer. Additionally, studies have shown that ZNF384 has been associated with the development of various types of cancer. For example, high levels of ZNF384 have been associated with the development of breast cancer.

The potential of ZNF384 as a biomarker also makes it an attractive target for cancer diagnosis and treatment. For example, if ZNF384 can be used as a biomarker for cancer, it may be possible to use it to develop non-invasive diagnostic tests for cancer. Additionally, if ZNF384 is found to be a potential drug target, it may be possible to use it as a target for cancer treatment by inhibiting its activity.

Conclusion

In conclusion, ZNF384 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and its involvement in various cellular processes make it an attractive target for research and treatment. Further studies are needed to fully understand the potential of ZNF384 as a drug target and biomarker.

Protein Name: Zinc Finger Protein 384

Functions: Transcription factor that binds the consensus DNA sequence [GC]AAAAA. Seems to bind and regulate the promoters of MMP1, MMP3, MMP7 and COL1A1 (By similarity)

The "ZNF384 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF384 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF385A | ZNF385B | ZNF385C | ZNF385D | ZNF385D-AS1 | ZNF385D-AS2 | ZNF391 | ZNF394 | ZNF395 | ZNF396 | ZNF397 | ZNF398 | ZNF402P | ZNF404 | ZNF407 | ZNF407-AS1 | ZNF408 | ZNF41 | ZNF410 | ZNF414 | ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430 | ZNF431 | ZNF432 | ZNF433 | ZNF433-AS1 | ZNF436 | ZNF436-AS1 | ZNF438 | ZNF439 | ZNF44 | ZNF440 | ZNF441 | ZNF442 | ZNF443 | ZNF444 | ZNF445 | ZNF446 | ZNF449 | ZNF45 | ZNF451 | ZNF454 | ZNF460 | ZNF461 | ZNF462 | ZNF467 | ZNF468 | ZNF469 | ZNF470 | ZNF471 | ZNF473 | ZNF473CR | ZNF479 | ZNF48 | ZNF480 | ZNF483 | ZNF484 | ZNF485 | ZNF486 | ZNF487 | ZNF488 | ZNF490 | ZNF491 | ZNF492 | ZNF493 | ZNF496 | ZNF497 | ZNF497-AS1 | ZNF500 | ZNF501 | ZNF502 | ZNF503 | ZNF503-AS1 | ZNF503-AS2 | ZNF506 | ZNF507 | ZNF510 | ZNF511 | ZNF512 | ZNF512B | ZNF513 | ZNF514 | ZNF516 | ZNF516-DT | ZNF517 | ZNF518A | ZNF518B | ZNF519 | ZNF519P3